Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18135561 | 0.91 | POLB (0.60) | MAPTALDH1A1RXFP1POLBTSHR | |
| SCHEMBL16825942 | 0.88 | POLB (0.63) | MAPTALDH1A1HPGDPOLBTSHR | |
| SCHEMBL16826124 | 0.86 | TDP1 (0.67) | MAPTALDH1A1POLBTSHRSMN1; SMN2 | |
| SCHEMBL16825726 | 0.79 | LMNA (0.52) | MAPTRXFP1KDM4EPOLBSMN1; SMN2 | |
| SCHEMBL23576456 | 0.79 | ALDH1A1 (0.61) | MAPTALDH1A1RXFP1HPGDTSHR | |
| SCHEMBL32671561 | 0.79 | ALDH1A1 (0.61) | MAPTALDH1A1RXFP1HPGDTSHR | |
| SCHEMBL16825929 | 0.78 | KDM4E (0.57) | MAPTALDH1A1RXFP1HPGDKDM4E | |
| SCHEMBL18135560 | 0.77 | LMNA (0.43) | MAPTALDH1A1RXFP1HPGDKDM4E | |
| SCHEMBL16826017 | 0.77 | KDM4E (0.46) | MAPTALDH1A1RXFP1KDM4EPOLB | |
| SCHEMBL16825684 | 0.77 | KDM4E (0.61) | MAPTALDH1A1RXFP1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3082805-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | The Institute For Drug Delivery (US) | 2016-10-26 | — | — | EP | claimed |
| US-20160297823-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | INSTITUTE FOR DRUG DISCOVERY, LLC | 2016-10-13 | — | — | US | claimed |
| WO-2015095701-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | THE INSTITUTE FOR DRUG DELIVERY (US) | 2015-06-25 | — | — | WO | claimed |
| EP-3082805-B1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | INST FOR DRUG DISCOVERY LLC (US) | 2020-02-05 | — | — | EP | disclosed |
| EP-3082805-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | The Institute For Drug Delivery (US) | 2016-10-26 | — | — | EP | disclosed |
| US-20160297823-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | INSTITUTE FOR DRUG DISCOVERY, LLC | 2016-10-13 | — | — | US | disclosed |
| US-20160297823-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | INSTITUTE FOR DRUG DISCOVERY, LLC | 2016-10-13 | — | — | US | disclosed |
| WO-2015095701-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | THE INSTITUTE FOR DRUG DELIVERY (US) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297823-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | CMA1, CHIA, AADAC | MAPT 2060/4885ALDH1A1 1006/4885RXFP1 2473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.